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ABSTRACT 
 
Development of optimal guideline for 
effective dendritic cell immunotherapy in mouse melanoma  
 
 
Han Kyoung Cho 
 
Department of Medicine  
The Graduate School, Yonsei University  
(Directed by Professor Min-Geol Lee) 
 
 
 
Mouse bone marrow-derived dendritic cells (DCs) were stimulated with 
tumor antigen alone or tumor antigen plus cocktail (anti-CD40 
antibody+TNF-α+IL-1β) for 8 hours, 24 hours or 48 hours, and the 
characteristics of DCs, such as surface molecules (CD40, CD80, CD86, 
MHC class II, and CCR7) on DCs, cytokines (IL-12, IFN-γ, and IL-10), 
DCs-induced T cell proliferation in vitro, and the production of IFN-γ by 
those T cells, were evaluated.  
 2 
Mice with melanoma were then treated with DCs stimulated with tumor 
antigen alone or tumor antigen plus cocktail for 8 hours or 48 hours. The 
tumor size and the survival rate of mice were then evaluated. In order to 
develop optimal guideline toward the determination of proper cell type for 
DCs immunotherapy in mouse melanoma, the functional characteristics of 
DCs were matched with the clinical efficacy of DCs immunotherapy.  
  
1) Beneficial clinical effects such as a reduction of tumor size and an 
increased survival rate were best observed in the group treated with DCs 
stimulated for eight hours with tumor antigen plus cocktail.  
2) The single prominent characteristic of DCs stimulated for eight hours 
with tumor antigen plus cocktail was an elevated IL-12 secretion. The 
cytokine IL-12 was not secreted by other DCs.   
Consequently, proper production of IL-12 was found to be an important 
functional guideline for DCs immunotherapy in mouse melanoma. 
Key words : dendritic cell, immunotherapy, melanoma, optimal guideline 
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I. INTRODUCTION  
 
Malignant melanoma is a potentially lethal cancer that arises from 
melanocytes present in the skin, mucosa, or the epithelial surfaces of the eyes 
and ears, and its incidence has increased substantially over the past two 
decades1, 2. Although primary tumor excision can sometimes achieve complete 
remission, most melanomas are beyond surgical margins when diagnosed, and 
are usually resistant to chemotherapy and radiotherapy3. Consequently, many 
other therapeutic modalities are being investigated, and one of them being 
dendritic cell-based immunotherapy4, 5.  
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Dendritic cells (DCs) are one of the most potent antigen-presenting 
cells6. DCs residing in the skin or mucosa are in their immature state and have 
great phagocytic capacity. After antigen uptake, DCs undergo maturation, 
noted by a downregulated antigen uptake and increased antigen processing 
ability. They then migrate to the regional lymph nodes (LNs) where they 
present antigen to naive T cells, which generate a potent host immunity to the 
antigen7. It has been reported that efficient antitumor immunity is generated 
by immature DCs because immature DCs phagocytose both necrotic and 
apoptotic tumor cells, and can mature in vivo8. The abilities of DCs to 
phagocytose tumor cells in vivo and migrate to regional LNs 24 hours after 
injection have also been demonstrated. These findings suggest that DCs can 
be used efficiently in cancer immunotherapy. Such DC-based 
immunotherapies have been attempted in mice and humans, and positive 
results have been obtained with many tumors, especially with malignant 
melanoma, B cell lymphoma, colorectal cancer, and prostate cancer9-12.  
 
Despite some favorable results, however, DCs immunotherapy has 
yet to show acceptable, reasonable clinical effects. To enhance clinical effects, 
DCs immunotherapy must have the ability to activate some effector cells such 
as cytotoxic T cells, helper T cells, B cells, natural killer (NK) cells, NK T 
cells or γ:δ T cells. In order to succeed in DCs immunotherapy, sufficient 
considerations of both dendritic cellular factors and non-dendritic cellular 
factors are essential13. Nestle et al. emphasized three parameters need to be 
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taken into account using DCs immunotherapy; the choice of antigen and 
adjuvant, the choice of injection site (localization) and the choice of timing 
and dosing14. There are many issues of DCs immunotherapeutic challenges, 
including; source and ex vivo manipulation of DCs; antigen preparation and 
loading; and, route of administration. In addition, methods of measuring the 
immune and clinical response need to be standardized and adopted using state 
of the art procedures14. Currently, there is no consensus among the literature 
regarding the optimal guideline to follow in the development of DCs   
immunotherapy. A successful clinical response with DCs immunotherapy 
may not entirely depend on simply finding of optimal guideline of DCs. 
However, establishing optimal guideline of DCs for immunotherapy must be 
the first step to successful DCs immunotherapy.       
 
In this study therefore, mouse bone marrow-derived DCs were 
prepared and were further stimulated with maturation factors for 8, 24 and 
48 hours. Then these several different types of DCs were injected into mice 
with malignant melanoma as a form of immunotherapy. By means of 
matching the functional characteristics of DCs with the clinical results 
obtained by DCs immunotherapy, we attempted to define optimal guideline 
of DCs for DCs immunotherapy in mouse melanoma. 
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II. MATERIALS AND METHODS  
 
1. Mice 
C57BL/6 female mice (6-10 weeks old) were purchased from Daehan 
Biolink (Seoul, Korea) and housed in pathogen-free units at the Yonsei 
Medical Research Center. 
 
2. Media and Cytokines 
Complete medium (CM) consisting of RPMI 1640 (Gibco, BRL, Grand 
Island, NY) supplemented with 10% heat-inactivated FBS (Gibco), 100IU/㎖ 
penicillin (Gibco), 100 ㎍/㎖ streptomycin (Gibco), 0.1mM nonessential 
amino acids (Sigma, Saint Louis, MO), 1mM sodium pyruvate (Sigma), 
10mM HEPES (Sigma), and 50μM 2-mercaptoethanol (Sigma). DMEM 
(Gibco) and RPMI 1640 were used to culture hybridoma cell lines.  
Recombinant mouse GM-CSF (rmGM-CSF) or recombinant mouse IL-4 
(rmIL-4) were purchased from Endogen (Woburn, MA) and used to generate 
DCs. Maturation cocktail containing anti CD-40 antibody, TNF-α and IL-1ß 
was used.  
 
3. Preparations of Bone Marrow-derived DCs  
Bone marrow cells were obtained from the tibias and femurs of C57BL/6 
mice (6-8 weeks old) and depleted of erythrocytes using commercial lysis 
buffer (Sigma). Bone marrow cells were then treated with a mixture of 
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antibodies (Abs) [anti-CD4 (GK1.5, TIB-207), anti-CD8 (53-6.72, TIB-105), 
anti-B220 (RA3-3A1/6.1, TIB-146), anti-I-Ab,d,q & I-Ed,k (M5/114.15.2, TIB-
120), anti-erythrocytes, neutrophils & B cells (J11d.2, TIB-183); all were 
obtained from the ATCC] for 30min at 4℃, and then treated with rabbit 
complement (Cedarlane, Ontario, Canada) for 1hour at 37℃. Cells were then 
layered onto lympholyte M (density: 1.0875±0.0010g/㎖, Cedarlane) 
gradients, centrifuged, and low-density interfaces were collected. Cells were 
washed three times with CM, and then incubated in CM supplemented with 
10ng/㎖ GM-CSF and 10ng/㎖ IL-4 in 24 well plates at 7-10×105/well. On 
the second day of culture, floating cells were gently removed and fresh 
medium containing GM-CSF and IL-4 was replaced. On day four, floating 
cells were harvested and fresh medium containing GM-CSF and IL-4 was 
replaced. These harvested cells were then plated in new 24 well plates in CM 
supplemented with 10ng/㎖ GM-CSF and 10ng/㎖ IL-4 at 5×105/㎖. On day 
six, non-adherent and loosely adherent proliferating DCs were collected and 
counted. 
 
4. Flow Cytometric Analysis  
To identify surface molecules expressed on DCs, cells were harvested on 
day 5 (D5), 6 (D6) and 7 (D7). Cells (6-10×105) were washed twice with 
0.4% BSA/PBS and stained for 30min at 4℃ with monoclonal Abs against 
CD11c (Pharmingen, San Diego, CA), CD80 (Pharmingen), CD86 
(Pharmingen) and MHC class II (I-Ab,d,q & I-Ed,k). Hamster IgG (Pharmingen) 
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and rat IgG2a (Pharmingen) were used as isotype control. After two washes 
with 0.4% BSA/PBS, secondary staining was performed using FITC-
conjugated F(ab’)2 goat anti-rat Ig’s (Biosource, Camarillo, CA) and FITC-
conjugated anti-hamster IgG (Pharmingen). After 30min, cells were washed 
twice with 0.4% BSA/PBS and resuspended in 400 ㎕ of 0.4% BSA/PBS. 
Propidium iodide (Sigma) was added to exclude dead cells from the analysis. 
Flow cytometric analysis was performed on a FACSCalibur (Becton 
Dickinson, Mountain View, CA). 
 
5. Experimental Design  
In vitro 
Prepared DCs were grouped by an additional stimulation method and time. 
Group 1, group 2, and group 3 were incubated for 8 hours, 24 hours and 48 
hours, respectively with no additional stimulation. Group 4, 5, and 6 were 
incubated for 8 hours, 24 hours and 48 hours, respectively, under the 
stimulation of tumor antigen. Finally, group 7, 8, and 9 were incubated for 8 
hours, 24 hours and 48 hours, respectively, with stimulation of tumor antigen 
+ cocktail (anti CD-40 antibody, TNF-α and IL-1ß).  
 
In vivo  
A malignant melanoma model was made by inoculating 2.5×105 B16F10 
cells in 100 ㎕ PBS subcutaneously into C57BL/6 mice (6-10 weeks old). Six 
days later 50 mice were divided into five groups: 1) injected with PBS control 
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(10 mice, Group І), 2) injected with DCs stimulated for eight hours with 
tumor antigen (10 mice, Group Ⅱ), 3) injected with DCs stimulated for 48 
hours with tumor antigen (10 mice, Group Ⅲ), 4) injected with DCs 
stimulated for eight hours with tumor antigen plus cocktail (10 mice, Group 
Ⅳ), 5) injected with DCs stimulated for 48 hours with tumor antigen plus 
cocktail (10 mice, Group Ⅴ). 
 
6. Measurement of Tumor Size and Survival Rate 
After DCs immunotherapy of each grouped mice, tumor long and short 
axes were measured with calipers (Mitutoyo, Japan) at two to three day 
intervals. Tumor volumes were calculated using the formula: V=1/2×A2×B, 
where A is the length of the short axis and B that of the long axis. Surviving 
mice were counted until all group I mice succumbed. Survival rates were 
recorded as percentage survivals. 
 
7. Delayed Type Hypersensitivity Assay (DTH) 
Seven days after the third DCs injection, each mouse received 300 ㎍ of 
tumor lysates (suspended in 50㎕ of PBS) subcutaneously injected into the   
right footpad area. As a negative control, an identical amount of PBS was also 
injected into the left footpad of the same mouse. After 48 hours, the extent of 
swelling was measured using calipers (Mitutoyo). Results were reported as 
the differences in thickness (in millimeters) between both footpads. 
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8. T cell Proliferation Assay 
Splenocytes were obtained from each experimental group and commercial 
erythrocyte lysis buffer was added. After five min, the reaction was stopped 
by adding CM, then washed twice with CM. Triplicate samples of 1.5×105 
cells in CM were seeded in 96 well round-bottom plates (Corning, NY).  
Splenocytes (responder; R) were stimulated with B16F10 cells (stimulator; S) 
treated with mitomycin c and irradiation (30,000 rad) at a S:R ratio of 1:50. 
Splenocytes from untreated mice were used as negative control. The cells 
were incubated at 37℃ for 96 hours, then 1µCi/well [3H] thymidine was 
added for another 16 hours. Cells were harvested onto glass-fiber filters using 
a Harvester 96 (Tomtec, Hamden, CT), and [3H] thymidine incorporation 
(CPM) was counted on a scintillation counter (Wallac, Truku, Filand).  
 
9. IFN-γ ELISA  
To measure IFN-γ secreted by splenocytes, splenocytes were stimulated 
with B16F10 cells and prepared as described above. Quantities of secreted 
IFN-γ were measured by ELISA using an OptEIA set (Pharmingen) as 
described by the manufacturer. Briefly, anti-mouse IFN-γ Abs in 0.1M pH 9.5 
sodium carbonate (100㎕/well), were plated in the wells of 96 well plates 
(Corning) at 100㎕ per well and incubated overnight at 4℃. After washing, 
blocking solution (10% FBS/PBS) was plated at 200 ㎕ per well and 
incubated for 1 hour at room temperature (RT). After washing, culture 
supernatants were plated at 100㎕ per well and incubated for 2 hours at RT. 
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After washing, a mixture of biotinylated anti-mouse IFN-γ Ab and 
streptavidin-HRP reagent were plated at 100㎕ per well and incubated for 1 
hour at RT. After washing, substrate solution (100 ㎍/㎖ tetramethyl 
benzidine and 0.003% H2O2) was added at 100㎕ per well and incubated for 
30 min, at RT, in the dark, followed by 4 N HCl. OD450 was measured on an 
ELISA Reader (Molecular Devices, Sunnyvale, CA, USA).  
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III. RESULTS  
1. Analysis of DCs surface molecules. Erythrocyte-, lymphocyte-, and 
neutrophil-depleted bone marrow cells of C57BL/6 mice were incubated with 
rmGM-CSF and rmIL-4 for six days. After additional stimulation, the surface 
expressions of CD11c, CD40, CD80, CD86, MHC class II, and CCR7 on DCs 
were examined in each DCs group (Fig. 1). Upon flow cytometric analysis, 
moderate expression of CD11c was identified, which indicated that the DCs 
had been generated from bone marrow cells stimulated with rmGM-CSF and 
rmIL-4 (data not shown). DCs stimulated for 48 hours with tumor antigen 
plus cocktail showed moderate expression of CD80, CD86, and MHC class II. 
However, DCs cultured for 48 hours with no simulation, or with tumor 
antigen alone, showed only weak expressions of CD80, CD86, and MHC 
class II.  
 
2. Analysis of Intracytoplasmic Cytokines of DCs. Intracytoplasmic 
cytokines (IL-12p40/p70, Il-10, and IFN-γ) of each DCs groups were 
examined by flow cytometric analysis (Fig. 2). However, those cytokines 
were not stained in any experimental group.  
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Figure 1. Analysis of DCs Surface Molecules. The surface phenotypes of each additional stimulated DCs were examined by 
flow cytometry using CD40, CD80, CD86, MHC class II, CCR7. The expression of surface molecules on DCs were most 
increased in DCs stimulated for 48 hours with tumor antigen plus cocktail.   
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Figure 2. Analysis of Intracytoplasmic Cytokines of DCs. DCs stimulated with tumor antigen alone (group 4, 5, and 6) or tumor 
antigen + cocktail (group 7, 8, and 9) showed no expression of intracytoplasminc cytokines. (No;no treatment, Ag;Ag only, 
Ag+C;Ag+Cocktail) 
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3. Analysis of Cytokines Secreted by DCs. Cytokines secreted from DCs were 
measured by ELISA (Fig. 3). IL-12p40/p70 was detected in the tumor antigen 
plus cocktail stimulated group. DCs stimulated for eight hours with tumor 
antigen plus cocktail showed marked secretion of IL-12p40/p70 (2,065 pg/㎖). 
As incubation time passed, the amount of secreted IL-12p40/p70 decreased 
(24 hours 1,120 pg/㎖ and 48 hours 598 pg/㎖, respectively). However, IL-
12p40/p70 was not detected in control and the tumor antigen only stimulated 
groups. No groups showed IFN-γ, or IL-10 secretion (data not shown).       
 
4. T cell Proliferation Assay. Isolated T cells from spleen were used for T cell 
proliferation assay. The strongest T cell proliferation (7,253 cpm) was 
observed with DCs stimulated for eight hours with tumor antigen plus cocktail. 
Elevated T cell proliferative reactions were also observed with DCs 
stimulated for 24 or 48 hours with same methods (2,943 cpm and 2,983 cpm, 
respectively) (Fig. 4).  
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Figure 3. Analysis of Cytokines Secreted by DCs. DCS stimulated for 8 hours 
with tumor antigen plus cocktail showed more IL-12p40/p70 secretion (2,065 
pg/㎖) than 24 hours (1,120 pg/㎖) or 48 hours (598 pg/㎖) stimulated DCs.  
. 
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Figure 4. T cell Proliferation Assay After in vitro DCs-treatment. DCs 
stimulated for 8 hours with tumor antigen plus cocktail showed more T cell 
proliferation (7,253 cpm) than 24 hours (2,943 cpm) or 48 hours (2,983 cpm) 
stimulated DCs. 
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5. Analysis of Cytokines Secreted by DCs-stimulated T cells. IFN-γ, IL-
12p40/p70, and IL-10 were examined in culture media of T cells stimulated 
by DCs. IFN-γ secretion was most increased with T cells stimulated by eight 
hours with tumor antigen plus cocktail stimulated-DCs group (186 pg/㎖) 
(Fig. 5). As stimulation time passed, the rate of secretion was reduced (139 
and 132 pg/㎖ respectively). In T cells stimulated by tumor antigen only 
stimulated DCs, IFN-γ secretion was similar to control. IL-12 and IL-10 
were hardly detectable by T cells and its secretion showed no significant 
differences.     
 
6. Analysis of Tumor Sizes and Mice Survival Rate. Nineteen days after 
B16F10 injection to mice, tumor volume reduction was evident in the group 
treated with DCs stimulated for eight hours with tumor antigen plus cocktail 
(group Ⅳ), which showed a much reduced tumor volume(695±514 ㎣) than 
the control (group І, 2,020±808 ㎣). (Fig. 6) Mice treated with DCs 
stimulated for eight hours with tumor antigen only (group Ⅱ) also showed 
tumor volume reduction.  
The mice treated with DCs stimulated for eight hours with tumor 
antigen plus cocktail showed best survival rate (66 days, control 32 days) (Fig. 
7). The groups treated with DCs stimulated with tumor antigen alone also 
showed increased survival rates (8 hours at 46 days, and 48 hours at 42 days, 
respectively), but a survival benefit was not observed in mice treated with 
DCs stimulated for 48 hours with tumor antigen plus cocktail (33 days).  
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Figure 5. Analysis of Cytokines Secreted by DCs-stimulated T cells. IFN-γ 
secretion was most increased by T cells activated by DCs stimulated for eight 
hours with tumor antigen plus cocktail (186 pg/㎖).   
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Figure 6. Analysis of Tumor Size. Tumor volume was reduced in the group 
treated with DCs stimulated for eight hours with tumor antigen plus cocktail 
(695±514 ㎣, control 2,020±808 ㎣)  
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Figure 7. Analysis of Mice Survival Rate. Mice survival rate was increased in 
the group treated with DCs stimulated for eight hours with tumor antigen plus 
cocktail (66 days, control 32 days).   
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7. DTH.  All study groups produced a DTH reaction when compared to 
control group. The groups treated with 8 hour-stimulated DCs showed more 
potent DTH than 48 hour-stimulated DCs-treated groups. The most potent 
DTH reaction (1.0167㎜) was observed in the group treated with DCs 
stimulated for eight hours with tumor antigen plus cocktail (control, 0.1033 
㎜) (Fig. 8) 
 
8. T cell Proliferation Assay After DCs Immunotherapy. All study groups 
induced T cell proliferation in vitro when compared to control. Similar to the   
DTH reaction, 8 hour-stimulated DCs-treated groups showed stronger T cell 
proliferation in vitro than 48 hour-stimulated DCs-treated groups (Fig. 9).  
The strongest T cell proliferation (7,800 cpm) was observed in the group 
treated with DCs stimulated for eight hours with tumor antigen plus cocktail 
(control, 2,572 cpm).  
 
9. Cytokines Secretion After DCs Immunotherapy. Similar to the DTH and T 
cell proliferation assay, IFN-γ secretion was increased more in groups 
subjected to 8 hour-stimulated DCs than 48 hour-stimulated DCs. The highest 
IFN-γ secretion (30,148 pg/㎖) was observed in the group treated with DCs 
stimulated for eight hours with tumor antigen alone (Fig. 10).  
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Figure 8. DTH. Eight hour-stimulated DCs-treated groups showed stronger 
DTH reactions than 48 hour-stimulated DCs-treated groups.   
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Figure 9. T cell Proliferation Assay After DCs Immunotherapy. Eight hour-
stimulated DCs-treated groups showed stronger T cell proliferation than 48 
hour- stimulated DCs-treated groups. (C;Cocktail)   
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Figure 10. Cytokines Secretion After DCs Immunotherapy. IFN-γ secretion 
was more increased in 8 hour-stimulated DCs-treated groups than 48 hour-
stimulated DCs-treated groups 
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IV. DISCUSSION  
 
In this study, mouse bone marrow-derived DCs were generated and 
were further stimulated with tumor antigen alone or tumor antigen plus 
cocktail (anti-CD40 antibody + TNF-α + IL-1β) for 8 hours, 24 hours or 48 
hours, respectively. Then the characteristics of DCs, such as surface 
molecules (CD40, CD80, CD86, MHC class II, and CCR7), cytokines (IL-
12, IFN-γ, and IL-10) produced by DCs, DCs-induced T cell proliferation in 
vitro, and the production of IFN-γ by those T cells, were evaluated.   
 
Furthermore, mice with malignant melanoma were treated with DCs 
stimulated with tumor antigen alone or tumor antigen plus cocktail for 8 
hours or 48 hours, respectively. Then tumor size and survival rate were 
evaluated. By means of matching the functional characteristics of DCs with 
the clinical efficacy of DCs immunotherapy, we attempted to determine the 
optimal guideline of DCs for DCs immunotherapy in mouse melanoma. 
The best clinical responses in terms of tumor volume reduction and 
increased survival rate were observed with DCs stimulated for eight hours 
tumor antigen plus cocktail. DCs stimulated for eight hours with tumor 
antigen alone also showed improved clinical responses, but these responses 
were weaker than those induced by DCs stimulated with both tumor antigen 
and cocktail. Thus, we examined the characteristics of DCs stimulated for 
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eight hours with tumor antigen plus cocktail. These DCs expressed more IL-
12 than other groups. An in vitro T cell proliferation assay showed the 
strongest response with DCs stimulated for eight hours with tumor antigen 
plus cocktail. IFN-γ secretion by DCs-stimulated T cell was greater than 
other groups. Immunologic monitoring such as DTH, T cell proliferation, and 
IFN-γ secretion by T cells in vaccinated mice were also performed to compare 
the immune responses to clinical responses. All immunologic monitoring 
method showed that 8 hour-stimulated DCs-treated groups had stronger 
reactions than 48 hour-stimulated DCs-treated groups. With all of these 
functional characteristics of DCs, clinical responses, and immunologic 
reaction results, we concluded that proper secretion of IL-12 by DCs is an 
optimal guideline of DCs for DCs immunotherapy in mouse melanoma.  
In this study, the surface molecules (CD80, CD86, and MHC class 
II) were expressed the most in DCs stimulated for 48 hours with tumor 
antigen plus cocktail. However, clinical responses of this group were weaker 
than those induced by DCs stimulated for eight hours with same method. It is 
not fully known whether the status of DCs maturation is a major indicator of 
clinical efficacy. In some clinical studies, T cell stimulatory capacities of 
immature DCs are shown to be less, compared to mature DCs15. However, 
other clinical trials indicate immature DCs are superior to mature DCs, at least, 
with regard to the induction of T cell responses16, 17. Nevertheless, the 
consensus regarding the activation status of DCs for effective DCs 
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immunotherapy has not been reached. Generally, DCs stimulated with 
maturation factors are thought to be more potent in APC than immature 
DCs18,19. However, the APC function of DCs is thought to be limited to the 
later development of an immune response to avoid improper or autoimmune 
reaction. Several studies have shown that newly activated DCs express cell 
surface molecules at high levels and produce some factors required for T cell 
activation. However, DCs activated for long periods by maturation stimuli 
may not be functional immunologically 21-23. 
 
In this study, IL-12 secretion was detected at a higher level in DCs 
stimulated for eight hours with tumor antigen plus cocktail. However, control 
DCs and tumor antigen alone stimulated DCs showed no IL-12 secretion 
regardless of activation time. IL-12 is known to be a cytokine that is involved 
directly in the generation of CTL responses24. One study showed that after in 
vitro activation by LPS, as well as by poly(I)-poly(C), and TNF-α plus IL-1β, 
DCs produce IL-12 only transiently, with a peak between 5 and 8 hours, and 
complete extinction after 18 hours, the time at which they become refractory 
to further stimulation by CD40L23. There are similar results in the literature 
using microarray techniques25,26.  It is more intriguing that DCs activated for 
8 hours preferentially induced Th1 responses, but DCs activated for 48 hours 
induced Th2 responses and nonpolarized T cells23. Eight hours-stimulated 
DCs were previously observed to produce IL-12 maximally and move to 
regional lymphoid tissue efficiently27. It thus appears that eight hours-
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stimulated DCs induce CD4+ T cell activation27, possibly Th1 polarization28, 
and potent CTLs 29,30.  The so-called ‘gold standard’ mature DCs (cultured in 
IL-4 and GM-CSF in combination with IL-1β, IL-6, TNF-α, and PGE2) are 
known to have this handicap because of their low or absent production of IL-
1231, and the concern that fully maturated DCs are unable to induce immune 
responses preperly32. These problems are supported by some studies using so-
called ‘gold standard’ DCs, which showed relatively low levels of clinical 
responses14.  
 
To induce an Ag-specific T cell response, DCs maturation is 
essential33. Many agents have been used to induce DCs maturation 
experimentally such as monocyte conditioned medium34, cytokine mixture 
(consisting of TNF-α, IL-6, IL-1β, and PGE2)35, poly(I:C) (a synthetic analog 
of dsRNA)36, CpG oligonucleotides 37.38, and LPS39. It is known that poly(I:C), 
CpG oligonucleotides, and LPS show their effects on target cells by binding to 
endogenous TLRs (TLR3, 9, and 4)36,40-42. LPS-induced DCs maturation has 
been shown to markedly enhance the ability of Ag-loaded DCs to stimulate an 
Ag-specific T cell response in vitro and in vivo animal model33,43,44. 
Nevertheless, due to toxicity (potentially leading to toxic shock) and batch-to-
batch variability, the use of LPS for the maturation of DCs in clinical 
immunotherapy is limited45. In this study, DCs were also stimulated with 
tumor antigen plus LPS for 8, 24, or 48 hours. The expression of surface 
marker on those DCs was higher than tumor antigen alone or tumor antigen 
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plus cocktail stimulated-DCs.  IL-12 secretion was also increased to a greater 
level than DCs stimulated for eight hours with tumor antigen plus cocktail. 
Especially, the intracytoplasmic IL-12 was detected at a higher level in DCs 
treated with tumor antigen plus LPS stimulation for 8 hours whereas IL-12 
was nearly undetectable in DCs treated with tumor antigen plus cocktail 
stimulation for 24 or 48 hours. Ultimately, however, DCs vaccines have been 
investigated in regard to human disease, especially human cancer. Though the 
use of LPS for DCs maturation is expected to enhance Ag-specific immunity33, 
other substitutable clinically safe stimulation factors need to be developed.   
 
In summary, mouse bone marrow-derived DCs were generated using 
different stimulation method and incubation time. Then DCs immunotherapy 
on a malignant melanoma mouse model was performed. After DCs 
immunotherapy, functional characteristics of DCs that showed the best 
clinical responses including reduction of tumor size and increased survival 
rates were evaluated. DCs stimulated for eight hours with tumor antigen plus 
cocktail showed the best clinical responses. Moreover, those DCs had 
elevated IL-12 secretion whereas others showed no IL-12 secretion. Thus,    
proper production of IL-12 is shown to be the optimal guideline of DCs for 
DCs immunotherapy in mouse melanoma.  
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V. CONCLUSION 
In this study, functional characteristics of DCs stimulated by several 
maturation factors in vitro were examined. Then immunotherapy for 
murine malignant melanoma with prepared DCs was performed.  
1. The expression of surface molecules on DCs were most increased in 
DCs stimulated for 48 hours with tumor antigen plus cocktail.  
2. No intracytoplasmic cytokines (IL-12p40/p70, IL-10, IFN-γ) were 
detected in all groups by flow cytometric analysis.   
3. Il-12p40/p70 was detected in the culture supernatants of DCs 
stimulated for eight hours with tumor antigen plus cocktail by ELISA. 
However, IL-10, and IFN-γ were not detected in any groups. 
4. T cell proliferation assay in vitro was increased by DCs stimulated for 
eight hours with tumor antigen plus cocktail.   
5. IFN-γ secretion by DCs-stimulated T cells was induced to some 
degree by DCs stimulated for eight hours with tumor antigen plus 
cocktail.   
6. Tumor size was reduced in the group treated with DCs stimulated for 
eight hours with tumor antigen plus cocktail.  
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7. Most increased survival rate were observed in the group treated with 
DCs stimulated for eight hours with tumor antigen plus cocktail.  
8. Immunologic monitoring (DTH, T cell proliferation, IFN-γ secretion 
by T cells) showed that 8 hour-stimulated DCs are more immunogenic 
than 48 hour-stimulated DCs.      
Taken together, most effective immunotherapeutic results were induced 
by DCs stimulated for eight hours with tumor antigen plus cocktail. 
Consequently, proper production of IL-12 was thought to be the optimal 
guideline of DCs for DCs immunotherapy in mouse melanoma. 
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Abstract (in Korean) 
 
 마우스 악성흑색종의 효과적인 
수지상세포치료를 위한 최적조건 확립 
 
<지도교수 이민걸>  
 
연세대학교 대학원 의학과  
 
조  한  경   
 
 
 
마우스 골수세포로부터 얻은 수지상세포를 종양항원, 
종양항원+칵테일(항-CD40 항체+TNF-α+IL-1β)로 각각 8 시간, 
24 시간, 48 시간 동안 자극하여 수지상세포의 표면항원 
(CD40, CD80, CD86, MHC class II, CCR7) 발현 정도, 
수지상세포의 세포질 내 및 세포 배양액의 사이토카인 (IL-
12, IFN-γ, IL-10) 분비, 수지상세포의 자극에 의한 T 
세포의 증식반응 및 IFN-γ 생성 정도를 측정하였다. 또한 
악성흑색종이 유발된 마우스를 각 실험군 (8 시간과 48 시간 
군)의 수지상세포로 치료하여 임상적 유효성을 확인하였다.   
이 후 in vitro 에서 측정한 수지상세포의 특성과 in vivo 
면역치료 결과를 비교하여, 악성흑색종의 효과적인 
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수지상세포치료를 위한 수지상세포의 최적기준을 관찰하고자 
하였다.  
1) 악성흑색종에 대한 면역치료 결과 8 시간 동안 
종양항원과 칵테일로 자극한 수지상세포를 주사한 
실험군에서 종양크기의 감소, 생존율 증가 등의 임상적 
치료결과가 가장 좋았다.  
2) 8 시간 동안 종양항원과 칵테일로 자극한 수지상세포의 
특성을 살펴본 결과 다른 실험군의 수지상세포에 비하여 IL-
12를 많이 생성하는 것을 관찰하였다.  
이상의 결과로, 수지상세포의 충분한 IL-12 생성이 
악성흑색종의 효과적인 수지상세포치료를 위한 수지상세포의 
최적기준이라고 생각한다. 
핵심되는말 : 수지상세포, 흑색종, 면역치료, 최적기준  
 
